•
The total cost of GP consultations per annum is calculated by multiplying the cost per GP consultation by the total number of patients in the UK with AI and then multiplying by the number of GP consultations associated with the management of AI per annum. Total cost of GP consultations: £43 x 20,671 x 2 = £1,777,705
• The total drug cost is calculated by multiplying the cost of immediate release hydrocortisone per annum with the total number of patients in the UK with AI. Total drug cost: £1,049 x 20,671 = £21,694,129
• Total primary care cost = £23,471,833
• The total cost of OP visits is calculated by multiplying each type of attendance cost by the respective number of admissions. Total cost of OP visits: (41 x £230) + (11,184 x £106) = £1,194,826
• The total cost of admission for the management of AI is calculated by multiplying the cost per hospitalisation for management of AI by the number of hospitalisations per year for the management of AI. Total cost of admission for management of AI: £459 x 2,229 = £1,023,114
• The total cost of emergency admissions is calculated by multiplying the cost per hospitalisation for adrenal crisis by the number of adrenal crises per annum. This is then added to the number of adrenal crises requiring intensive care treatment, multiplied by the cost per day for intensive care treatment and multiplied by the length of stay (days). Total cost of emergency admissions for the management of AI: (£1,921 x 1,029) + (98 x £1,189 x 2) = £2,209,174
• Total secondary care cost = £4,427,114
• The total indirect cost is calculated by multiplying the number of days AI patients are absent from work by the average cost per day of a full time employee.
• • Treatment of patients with AI is based upon hormone replacement, and should aim to give the lowest effective dose, which alleviates symptoms. 4 • There is a clear circadian rhythm to glucocorticoid levels in humans. Levels fall throughout the day and the lowest levels are in the evening and around onset of sleep. Levels rise through the early hours to a peak around 8am, or soon after waking. 5, 6 • AI treatment aims to reproduce natural cortisol levels, mimicking the natural cortisol profile avoids the side affects attributed to under and over treatment (discussed in further detail below).
• The effect of current therapy on cortisol levels versus that of a healthy volunteer can be seen in Figure 1 .
Conclusions
• The high healthcare and social costs associated with AI highlight the clinical and economic need to improve RT.
• Drug costs and lost productivity are the main drivers of the COI in AI based on this analysis.
• The total is likely to be significantly higher due to (i) premature mortality; (ii) the costs associated with the management of co-morbidities; and (iii) the costs of lost productivity due to co-morbidities.
• Furthermore, as some consequences of the disease (such as; depression, cardiovascular problems, fractures and diabetes) were not included in these calculations, £39.7 million per annum is likely to be a considerable underestimate of the true burden of disease. This study was funded by ViroPharma Holdings Limited. BresMed received consultancy fees from ViroPharma Holdings Limited. Table 1 : Primary care costs and resource use
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• When planning a treatment regimen there is a balance required for each patient. On the one hand, there are risks associated with over-treatment with steroids, particularly over exposure during the afternoon, evening and night-time, including: [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] − Increased standardised mortality rate, mainly from cardiovascular disorders [9] [10] [11] [12] − Impaired well-being and quality of life [13] [14] [15] − Poor metabolic profile 16, 17 − Reduced bone mineral density 18, 19 On the other hand, there are risks associated with under-treatment with steroids, such as adrenal crisis. 1 • AI patients with diabetes are more vulnerable than other AI patients because it is more difficult to control their glucose level due to the simultaneous need for glucocorticoid replacement. 20
Methods
• Using Arlt and Allolio 2 , the prevalence of primary AI in westernized populations is estimated to be between 0.93 and 1.40 per 100,000 and for secondary AI between 1.50 and 2.80 per 100,000.
• Using these figures, in England and Wales, the estimated patient numbers are in the order of ‫006,-ם001,5‬ Mean healthy volunteers (n=13) 7 Immediate release hydrocortisone tablet (observed patient data, n=64) 8 
Objective
•
To calculate the cost of illness (COI) associated with AI in the UK.
• A budget impact model, was developed to capture the cost implications of AI in the UK.
• Direct costs were estimated using national reference costs, Payment by Results tariffs and other published data.
• AI prevalence and adrenal crises data were taken from published literature and activity data (hospital admissions for management of AI) from Hospital Episode Statistics (HES) data.
• A 2012 worldwide survey of AI patients 3 was used to determine days taken off work. Clinical expert opinion was sought to determine GP and outpatient appointments per year.
• The costs associated with premature mortality, the treatment and management of co-morbidities, and the burden associated with reduced quality of life were not included due to lack of data.
• The COI includes the cost of RT, primary and secondary care costs (GP and outpatient (OP) appointments; admissions for adrenal crises; diagnosis and management of AI) and those associated with reduced productivity (absenteeism).
• Tables 1-3 show the key model inputs.
